About

Dr John Pritchard, PhD, Chairman of Nebu~Flow, is a private consultant specialising in strategic approaches to developing respiratory devices, drugs and digital health.

At different stages in his career across three major pharmaceutical companies, he has been associated with the launch of 11 major products and, at the Respiratory Drug Delivery conference in April 2018 (RDD 2018), Dr Pritchard received the Charles G Thiel award for outstanding research and discovery in respiratory drug delivery.

He has published widely in the field, as well as having served as a board member on various scientific and industry bodies. He is currently a member of the UN Committee that makes recommendations on the essential uses of propellants.

Contributions

PULMONARY

INNOVATIVE ACOUSTIC NEBULISER TECHNOLOGY

Andrea Cusack, Elijah Nazarzadeh and John Pritchard share insights into the company’s innovative nebuliser platform, designed to overcome the technical restrictions of current technologies that limit the delivery of advanced medicines to the lungs. They also share an update on the development of new digital features for the Nebu-Flow product range.

More contributions

EARLY INSIGHT

CREATING A PLATFORM FOR NEBULISATION OF A WIDE RANGE OF DRUG TYPES AND FORMULATIONS

Elijah Nazarzadeh and John Pritchard introduce Nebu~Flow – a novel class of nebuliser technology that represents a major step in the ability to deliver drugs efficiently to the lungs. overcoming the limitations of current systems and unlocking the potential of the inhalation route, including for systemic delivery.

EXPERT VIEW

NEBULISERS: TIME TO REINVENT THE WHEEL

John Pritchard discusses the history of the nebuliser, its fall in popularity with the advent of DPIs and pMDIs, and its current resurgence due to the success of the mesh nebuliser, continuing on to how changing the development paradigm to utilise nebuliser technology more effectively can have significant benefits.